Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome

Metabolic abnormalities are well-known risk factors for many cancers, even though no clearly established link with pancreatic neuroendocrine neoplasms (PanNENs) has yet been investigated. This research aimed to assess the serum levels of leptin, chromogranin A (CgA), carbohydrate antigen 19-9 (CA19-...

Full description

Bibliographic Details
Main Authors: Violetta Rosiek, Agnes Bocian-Jastrzębska, Beata Kos-Kudła
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/15/8/2348